 Home > Active Ingredient News > Study of Nervous System > NICE UK rejects Zeposia's role in treating multiple sclerosis

NICE UK rejects Zeposia's role in treating multiple sclerosis

 Last Update: 2021-02-01
 Source: Internet
 Author: User

Tags

victoza drug class

european food

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The National Institute for Health and Care Excellence (NICE) has rejected an application by BMS's Zeposia (ozanimod) to treat relapse-difficult multiple sclerosis (RRMS).
,
NICE said in an evaluation consultation that while there is evidence that Zeposia can reduce the number of relapses and brain lesions in patients with multiple sclerosis compared to interferon beta-1a, it is not clear how the drug affects disability progression.
nice also said zeposia's cost-benefit estimate was uncertain because of "limitations" in clinical effectiveness evidence.
last May, Zeposia was approved by the European Medicines Agency for treatment with RRMS, and last year it was approved by the U.S. Food and Drug Administration (FDA).
sarah Rawlings, director of research and external affairs at the MS Association, said: "It is disheartening that NICE has decided not to recommend Zeposia for the treatment of MS.
although there are many treatments for this condition, oral drugs are still scarce and people can benefit greatly from a new, more convenient alternative.
decision is not final and we urge them and the manufacturer to review the evidence and consider which method is best for MS patients."

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Pregabalin (CNS)

CAS No.: 148553-50-8

Pharmacy Grade

$1/KG FOB

Primidone CAS125-33-7

CAS No.: 125-33-7

Pharmaceutical Grade

$100/KG EXW

API Clomipramine HCl

CAS No.: 17321-77-6

Pharmacy Grade

$40-50/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.